Which federal agency does American Pharmacists Association (APhA) comment on most?

American Pharmacists Association (APhA) is most active at the Food and Drug Administration.

← OpenPolis Sign in

American Pharmacists Association (APhA)

Unclaimed

Industry

Nonprofit Organization Management

Staff

140

2215 Constitution Avenue Northwest, Washington, DC

Phone

+1 202-628-4410

Website

pharmacist.com

Engagement overview

American Pharmacists Association (APhA) has filed 230 public comments across 202 dockets at 17 federal agencies, most actively at the Food and Drug Administration.

American Pharmacists Association (APhA)

Engagement overview

Is this your organization?

Agency footprint

Dockets · FDA (140)

Drug Repurposing for Unmet Medical Needs; Request for Information

Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments--Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments – United States (U.S.) 2026-2027 Formula for COVID-19 Vaccine Composition.

Increasing Availability of Nonprescription Drugs; Request for Information

Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection: Draft Guidance for Industry; Availability

Developing Specifications for In-Home Disposal Systems for Opioid Analgesics Dispensed in an Outpatient Setting; Establishment of a Public Docket; Request for Comments

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments – United States (U.S.) 2026-2027 Influenza Vaccine Strain Composition

Food and Drug Administration Expert Panel on Testosterone Replacement Therapy for Men; Request for Information

Agency Information Collection Activities; Proposed Collection; Comment Request; Human Drug Compounding Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act

Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use

Improving Anaphylaxis Outcomes: Approaches for Enhancing Access to Epinephrine; Public Workshop; Request for Comments

Agency Information Collection Activities; Proposed Collection; Comment Request; Proposed Small Dispensers Assessment under the Drug Supply Chain Security Act

Compounding of Human Drug Products Under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket

Agency Information Collection Activities; Proposed Collection; Comment Request; Compounding Animal Drugs from Bulk Drug Substances

Use of Orally Ingestible Unapproved Prescription Drug Products Containing Fluoride in the Pediatric Population; Public Meeting; Establishment of a Public Docket; Request for Comments

Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments -- 2025-2026 formula for COVID-19 vaccines for use in the United States: Meeting Date: May 22, 2025.

Medication Guides: Patient Medication Information; Proposed Rule

Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act; Establishment of a Public Docket; Request for Information and Comments

CDRH Seeks public comment: Digital Health Technologies for Detecting Prediabetes and Undiagnosed Type 2 Diabetes

Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the FD&C Act

Labeling for Biosimilar Products

Reauthorization of the Over-the-Counter Monograph Drug User Fee program; Public Meeting; Request for Comments

Development of Small Dispensers Assessment under the Drug Supply Chain Security Act; Request for Comments

In-Home Safe Disposal Systems; Request for Information

Nonprescription Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

Petitioner requesting FDA to issue a final rule removing oral phenylephrine from the Final Monograph for OTC nasal decongestant drug products and to remove phenylephrine bitartrate from the 2006 amendment.

Joint Meeting of the Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments

DSCSA Implementation and Readiness Efforts for 2023; Public Meeting; Request for Comments

DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs: How to Exchange Product Tracing Information; Availability

Nonprescription Drug Product With an Additional Condition for Nonprescription Use; Proposed Rule

Revising the National Drug Code Format and Drug Label Barcode Requirements

Identifying Trading Partners Under the Drug Supply Chain Security Act

National Standards for the Licensure of Wholesale Drug Distributors and Third-Party Logistics Providers

Providing Mail-Back Envelopes and Education on Safe Disposal With Opioid Analgesics Dispensed in an Outpatient Setting; Establishment of a Public Docket; Request for Comments

Medical Devices; Ear, Nose, and Throat Devices; Establishing Over-the-Counter Hearing Aids and Aligning Other Regulations

Generic Drug User Fee Amendments; Public Meeting; Request for Comments

Hospital and Health System Compounding Under the Federal Food, Drug, and Cosmetic Act

Biosimilar User Fee Act

Reconsidering Mandatory Opioid Prescriber Education Through a Risk Evaluation and Mitigation Strategy (REMS) in an Evolving Opioid Crisis; Public Workshop; Request for Comments

Reauthorization of the Prescription Drug User Fee Act; Public Meeting; Request for Comments

Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act

Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act

The Drug Supply Chain Security Act Pilot Project Program and Enhanced Drug Distribution Security; Public Meeting; Request for Comments

Dual Agency - HHS Federal Register Notices (FRN) without a docket ID which includes FDA data or supported related material

Covington & Burling LLP on behalf of PhRMA, PSM and CAHC respectfully request that the U.S. Food and Drug Administration refrain from authorizing the Proposal and disclose the identities of Foreign Sellers for public comments

Fixed-Quantity Unit-of-Use Blister Packaging for Certain Immediate-Release Opioid Analgesics for Treatment of Acute Pain; Establishment of a Public Docket; Request for Comments

Risk Evaluation and Mitigation Strategy Assessment Summary for Web Posting; Establishment of a Public Docket; Request for Comments

Approved Drug Products With Therapeutic Equivalence Evaluations (the Orange Book); Establishment of a Public Docket; Request for Comments

Prescription Drug User Fee Act

Policy for Compounding of Certain Alcohol-Based Hand Sanitizer Products Through April 30, 2020; Immediately in Effect Guidance for Industry

Importation of Prescription Drugs

Importation of Certain FDA-Approved Human Prescription Drugs, Including Biological Products, under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry; Availability

Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products; Draft Guidance for Industry; Availability

Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived Compounds; Public Hearing; Request for Comments

The Future of Insulin Biosimilars: Increasing Access and Facilitating the Efficient Development of Biosimilar and Interchangeable Insulin Products; Date for Public Hearing; Request for Comments

Nonproprietary Naming of Biological Products

REMS Assessment: Planning and Reporting; Draft Guidance for Industry; Availability

Prescription Drug-Use-Related Software; Establishment of a Public Docket; Request for Comments

Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs; Draft Guidance for Industry; Availability

Identifying the Root Causes of Drug Shortages and Finding Enduring Solutions; Public Meeting; Request for Comments

Future Format of the National Drug Code; Public Hearing; Request for Comments

Insanitary Conditions at Compounding Facilities

Memorandum of Understanding Addressing Certain Distributions of Compounded Drug Products Between the States and the Food and Drug Administration; Revised Draft; Availability

Innovative Approaches for Nonprescription Drug Products; Draft Guidance for Industry; Availability

Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products -- Content and Format; Draft Guidance for Industry; Availability

Waivers of the Single, Shared System Risk Evaluation and Mitigation Strategy Requirement

Development of a Shared System Risk Evaluation and Mitigation Strategy

Fulfillment of 21st Century Cures Act Section 3060 Required Report

Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability.

Drug Products Labeled as Homeopathic

Opioid Policy Steering Committee prescribing intervention – exploring a strategy for implementation; Public Hearing; Request for Comments

Enhanced Drug Distribution Security under the Drug Supply Chain Security Act; Public Meetings; Request for Comments

DSCSA Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier

Review of Existing Center for Devices and Radiological Health Regulatory and Information Collection Requirements

Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications